Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS

Monte Rosa Therapeutics (NASDAQ:GLUE) announced its earnings results on Tuesday. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10), FiscalAI reports. The firm had revenue of $2.78 million during the quarter, compared to the consensus estimate of $17.09 million. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE traded down $0.26 on Wednesday, hitting $15.77. 326,143 shares of the company were exchanged, compared to its average volume of 1,621,251. The company’s 50 day moving average price is $20.13 and its two-hundred day moving average price is $14.75. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $25.77. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of 49.16 and a beta of 1.63.

Wall Street Analyst Weigh In

GLUE has been the topic of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Guggenheim cut their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday. TD Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Zacks Research lowered Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $32.80.

Insider Activity

In related news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer directly owned 613,471 shares in the company, valued at $10,993,400.32. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Edmund Dunn sold 25,164 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $18.10, for a total value of $455,468.40. Following the completion of the transaction, the insider directly owned 22,693 shares of the company’s stock, valued at approximately $410,743.30. This trade represents a 52.58% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 36,771 shares of company stock valued at $693,692. 6.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of Monte Rosa Therapeutics in the 3rd quarter valued at $32,000. Lazard Asset Management LLC increased its stake in Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after acquiring an additional 3,262 shares during the period. Prudential Financial Inc. acquired a new position in Monte Rosa Therapeutics in the second quarter worth about $54,000. BNP Paribas Financial Markets lifted its stake in Monte Rosa Therapeutics by 88.3% during the third quarter. BNP Paribas Financial Markets now owns 9,733 shares of the company’s stock worth $72,000 after purchasing an additional 4,565 shares during the period. Finally, Sei Investments Co. acquired a new stake in Monte Rosa Therapeutics during the second quarter valued at approximately $74,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.